Grunbaum Z, Kroll K, Greene J L, Rasey J S, Krohn K A
Department of Radiology, University of Washington Medical Center, Seattle 98195.
Int J Rad Appl Instrum B. 1990;17(5):473-8. doi: 10.1016/0883-2897(90)90166-x.
[35S]L-Homocysteine thiolactone ([35S]L-HCTL) was synthesized and its biodistribution evaluated as a potential brain radioprotective agent and as a tissue hypoxia marker. Drug uptake in mouse brain exceeded that in s.c. tumor 3 h post injection only. Multiple indicator dilution experiments in the rabbit heart indicate that membrane permeability of [35S]L-HCTL does not limit its usefulness as a hypoxia marker. In addition, a positive correlation was observed between regional coronary blood flow and myocardial content of [35S]adenosylhomocysteine formed from [35S]homocysteine and adenosine.
合成了[35S]L-同型半胱氨酸硫内酯（[35S]L-HCTL），并评估了其作为潜在脑辐射防护剂和组织缺氧标志物的生物分布。仅在注射后3小时，小鼠脑中的药物摄取量超过皮下肿瘤中的摄取量。在兔心脏中进行的多次指示剂稀释实验表明，[35S]L-HCTL的膜通透性并不限制其作为缺氧标志物的用途。此外，观察到局部冠状动脉血流量与由[35S]同型半胱氨酸和腺苷形成的[35S]腺苷同型半胱氨酸的心肌含量之间呈正相关。
